Novartis’ Sandoz division has announced a new UK headquarters based in Camberley, Surrey.
The global leader in generics and biosimilars announced that it has opened the new building at Watchmoor Park, forming part of the company’s “Transforming Sandoz” strategy, which aims to enable the business to “strengthen its role as a leading provider of medicines to the NHS.”
The company says that the site will be the centre of its UK operations, which encompasses a range of operational functions. It also announced that it is “are hugely excited” to be opening the “new home”, and that “The move is part of our mission to build a long-term future in the UK and to continue working with the NHS to ensure access to generic medicines and biosimilars” said Timothy de Gavre, Sandoz UK country head.
He continued, “Watchmoor Park is the right home for us and our customers; offering convenience, an ideal location and appropriate facilities for our business requirements. As a company, we are on an exciting journey and we look forward to supporting the progress of Watchmoor Park as a thriving
By Anna Smith
Source: PharmaTimes
Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.
Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.
Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.
